{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-271117","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2026-06-15T20:15:51+00:00","discovered_at":"2026-06-15T20:17:00.330770+00:00","generated_at":"2026-06-15T20:27:18.794052+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adaptive Biotechnologies proposes $250M notes offering, plans MRD/Immune Medicine separation","bullets":["Intends to issue $250M convertible senior notes due 2031 (plus $37.5M option) to qualified institutional buyers.","Proceeds to repay OrbiMed Purchase Agreement (~$156.9M), repurchase up to $25M stock, and fund capped calls.","Plans to separate MRD and Immune Medicine businesses; expects to identify preferred path by year-end 2026.","MRD revenue grew to $212M in 2025 (from $103M in 2023), with $15M adjusted EBITDA.","Immune Medicine has over 6M functional TCR-antigen pairs and data on 10,000+ patients; evaluating alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-271117","json":"https://secwatch.observer/filing/0001193125-26-271117.json","markdown":"https://secwatch.observer/filing/0001193125-26-271117.md","text":"https://secwatch.observer/filing/0001193125-26-271117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000119312526271117/0001193125-26-271117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000119312526271117/d65233d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:27:18.794052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}